Related Experiment Videos
Scintigraphic evaluation of glomus tumours
T A Rockall1, J C Watkinson, S E Clark
1Department of Otolaryngology, Guys Hospital, London.
The Journal of Laryngology and Otology
|January 1, 1990
Summary
Glomus jugulare tumors can now be evaluated using both Iodine-131/123 metaiodobenzylguanidine (MIBG) and Technetium-99m (Tc99m) (v) dimercaptosuccinic acid (DMSA) scans. This study reports the first glomus jugulare tumor case positive for both imaging agents.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Current imaging for glomus tumors includes angiography, CT, and MRI, providing anatomical but not functional data.
- Radionuclide scintigraphy offers physiological insights, with Iodine-131/123 metaiodobenzylguanidine (MIBG) used for neuroendocrine tumors.
- Technetium-99m (Tc99m) (v) dimercaptosuccinic acid (DMSA) is a newer agent for head and neck tumors like medullary carcinoma of the thyroid (MCT).
Observation:
- A patient with a glomus jugulare tumor underwent evaluation using both I131/I123-MIBG and Tc99m (v) DMSA.
- The glomus jugulare tumor demonstrated positive uptake for both I131-MIBG and Tc99m (v) DMSA.
- This represents the first reported case of a glomus jugulare tumor exhibiting positive accumulation of both imaging agents.
Findings:
- The glomus jugulare tumor was functional, confirmed by positive uptake on both I131-MIBG and Tc99m (v) DMSA scintigraphy.
- The study successfully utilized dual-tracer radionuclide imaging for glomus tumor evaluation.
- The patient received therapeutic Iodine-131-MIBG treatment following diagnostic imaging.
Implications:
- Dual-tracer scintigraphy with I131-MIBG and Tc99m (v) DMSA can provide valuable functional information for glomus jugulare tumors.
- This approach may enhance diagnostic accuracy and treatment planning for glomus tumors.
- Further research is warranted to explore the broader clinical utility of these radionuclide agents in glomus tumor management.